Thanks for providing that quote Cabel. One can also see read imtesty's generous transcript of slide 13 from the AGM for this quote. This issue has been covered ad nauseum, IMO. I have no idea what DM meant by the quote. It is not backed up by apabetalone Phase 2 post-hoc analyses.

Just look at the Atherosclerosis 2016 paper and you can see that in the combined SUSTAIN/ASSURE post-hoc, there were only 35 total 5-point MACE events (18 in apabetalone group, 17 in placebo group.....note there were twice as many patient in apabetalone group). Of those 35, only 8 were 3-point MACE (4 non-fatal MI, 4 death). 4 MI and 1 death in the apabetalone group; 0 MI and 3 deaths in the placebo group. That is for the entire patient population. 8 out of 35 is only ~23%. 8 total 3-point MACE events are too few to put too much reliability in a 3-point MACE RRR.

At ESC 2014, but not in the Atherosclerosis paper, the breakdown of SUSTAIN/ASSURE MACE events in diabetics, which is an inclusion criteria for BETonMACE, was shown. In diabetics, there were 14 5-point MACE events (5 in apabetalone group, 9 in placebo group). Of those 14, only 3 were 3-point MACE (2 deaths in placebo group, 1 MI in apabetalone group). 3 out of 14 is ~21%. 3 total 3-point MACE events are too few to put any reliability into a 3-point MACE RRR.